131 related articles for article (PubMed ID: 1637660)
1. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug.
Lemaire L; Malet-Martino MC; de Forni M; Martino R; Lasserre B
Br J Cancer; 1992 Jul; 66(1):119-27. PubMed ID: 1637660
[TBL] [Abstract][Full Text] [Related]
2. [Cardiotoxicity of 5-fluorouracil: a question of formulation].
Lemaire L; Arellano M; Malet-Martino MC; Martino R; De Forni M
Bull Cancer; 1994 Dec; 81(12):1057-9. PubMed ID: 7742593
[TBL] [Abstract][Full Text] [Related]
3. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate.
Arellano M; Malet-Martino M; Martino R; Gires P
Br J Cancer; 1998; 77(1):79-86. PubMed ID: 9459149
[TBL] [Abstract][Full Text] [Related]
4. The tris formulation of Fluorouracil is more cardiotoxic than the sodium-salt formulations.
Lemaire L; Maletmartino M; Martino R; Deforni M; Lasserre B
Oncol Rep; 1994 Jan; 1(1):173-4. PubMed ID: 21607331
[TBL] [Abstract][Full Text] [Related]
5. Fluoroacetaldehyde as cardiotoxic impurity in fluorouracil (Roche).
Lemaire L; Malet-Martino MC; Longo S; Martino R; de Forni M; Carton M
Lancet; 1991 Mar; 337(8740):560. PubMed ID: 1671927
[No Abstract] [Full Text] [Related]
6. 5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model.
Arellano M; Malet-Martino M; Martino R; Spector T
Br J Cancer; 1997; 76(9):1170-80. PubMed ID: 9365165
[TBL] [Abstract][Full Text] [Related]
7. 31P-topical nuclear magnetic resonance (31P-TMR) studies of cardiotoxic effects of 5-fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR).
Tamatsu H; Nakazawa M; Imai S; Watari H
Jpn J Pharmacol; 1984 Apr; 34(4):375-9. PubMed ID: 6233441
[TBL] [Abstract][Full Text] [Related]
8. Hydrolytic pathway of 5-fluorouracil in aqueous solutions for clinical use.
Legay R; Massou S; Azéma J; Martino R; Malet-Martino M
J Pharm Biomed Anal; 2014 Sep; 98():446-62. PubMed ID: 25038499
[TBL] [Abstract][Full Text] [Related]
9. A 13C NMR study of 2-(13)C-chloroacetaldehyde, a metabolite of ifosfamide and cyclophosphamide, in the isolated perfused rabbit heart model. Initial observations on its cardiotoxicity and cardiac metabolism.
Loqueviel C; Malet-Martino M; Martino R
Cell Mol Biol (Noisy-le-grand); 1997 Jul; 43(5):773-82. PubMed ID: 9298599
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
11. 31P NMR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity-related changes in ATP, 2,3-BPG, and O2 metabolism.
Spasojević I; Zakrzewska J; Bacić GG
Ann N Y Acad Sci; 2005 Jun; 1048():311-20. PubMed ID: 16154943
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxic effects of 5-fluorouracil in the guinea pig.
Matsubara I; Kamiya J; Imai S
Jpn J Pharmacol; 1980 Dec; 30(6):871-9. PubMed ID: 7241861
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials.
Lukaschek J; Nufer M; Maurer D; Asanger M; Honegger H; Widmer L; Malet-Martino M; Legay R; Martino R
J Clin Oncol; 2004 Dec; 22(24):5022-5. PubMed ID: 15611524
[No Abstract] [Full Text] [Related]
14. Isolation of an aldehyde dehydrogenase involved in the oxidation of fluoroacetaldehyde to fluoroacetate in Streptomyces cattleya.
Murphy CD; Moss SJ; O'Hagan D
Appl Environ Microbiol; 2001 Oct; 67(10):4919-21. PubMed ID: 11571203
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study.
Akhtar SS; Salim KP; Bano ZA
Oncology; 1993; 50(6):441-4. PubMed ID: 8233284
[TBL] [Abstract][Full Text] [Related]
16. Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump.
Fournet A; Gilard V; Malet-Martino M; Martino R; Canal P; De Forni M
Cancer Chemother Pharmacol; 2000; 46(6):501-6. PubMed ID: 11138464
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
de Forni M; Malet-Martino MC; Jaillais P; Shubinski RE; Bachaud JM; Lemaire L; Canal P; Chevreau C; Carrié D; Soulié P
J Clin Oncol; 1992 Nov; 10(11):1795-801. PubMed ID: 1403060
[TBL] [Abstract][Full Text] [Related]
18. Increased iron content in rat myocardium after 5-fluorouracil chronic administration.
Millart H; Kantelip JP; Platonoff N; Descous I; Trenque T; Lamiable D; Choisy H
Anticancer Res; 1993; 13(3):779-83. PubMed ID: 8317911
[TBL] [Abstract][Full Text] [Related]
19. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits.
Cwikiel M; Zhang B; Eskilsson J; Wieslander JB; Albertsson M
Scanning Microsc; 1995 Jun; 9(2):561-76. PubMed ID: 8714749
[TBL] [Abstract][Full Text] [Related]
20. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
